Primary business concerns related to COVID-19 for pharma companies: Survey results

21 December 2020 (Last Updated December 21st, 2020 22:56)

Revenues of pharmaceutical companies have remained unscathed during the COVID-19 pandemic although operations were disrupted during the lockdowns imposed to curb its spread.

Revenues of pharmaceutical companies have remained unscathed during the COVID-19 pandemic although operations were disrupted during the lockdowns imposed to curb its spread.

GlobalData has conducted a survey to assess the primary concerns related to the COVID-19 outbreak for pharmaceutical companies dealing with drugs in different stages of development, including companies without marketed drugs, companies with predominantly marketed drugs​, and companies with pipeline and marketed drugs​.

Primary business concerns related to Covid-19 outbreak by company type

Primary concerns for pharmaceutical businesses related to the COVID-19 outbreak by company type

Analysis of the survey results shows that employee safety was the primary concern for companies. The concern was relatively lower for companies without marketed drugs and has decreased further in Q3, to 17% from 20% in Q1.

Companies with predominantly marketed drugs had a higher concern over employee safety, at 21% in Q1. The concern increased significantly to 32% by Q3.

Employee safety as a concern increased for companies with pipeline and marketed drugs as well, from 22% in Q1 to 24% in Q3.

Clinical trial disruption was the second biggest primary concern for companies without marketed drugs and has increased from 19% in Q1 to 22% in Q3.

Impact on supply chain was the second most primary concern for the other company types as classified by the survey. It was a concern for 21% in Q1 for companies with predominantly marketed drugs and those with pipeline and marketed drugs. The concern increased to 26% in Q3 for companies with predominantly marketed drugs but decreased for companies with pipeline and marketed drugs, to 19%.

Supply chain disruption was a relatively lesser concern for companies without marketed drugs, at 18% in Q1 and 17% in Q3.

The concerns regarding clinical trial disruption declined for companies with pipeline and marketed drugs (from 16% in Q1 to 15% in Q3) as well as for companies with predominantly marketed drugs (from 9% in Q1 to 0% in Q3).

The concerns regarding CRO disruptions increased significantly for companies with predominantly marketed drugs from 1% in Q1 to 10% in Q3 and slightly for companies without marketed drugs (from 16% in Q1 to 17% in Q3). It, however, declined for companies with pipeline and marketed drugs, from 9% in Q1 to 7% in Q3.

Business development concerns increased for companies without marketed drugs and companies with pipeline and marketed drugs, while it decreased for companies with predominantly marketed drugs.

Concerns regarding medical meeting closures declined for companies with predominantly marketed drugs and companies with pipeline and marketed drugs, while it increased for companies without marketed drugs.

Other concerns increased for companies without marketed drugs and those with pipeline and marketed drugs, while it declined for companies with predominantly marketed drugs.

The analysis is based on responses received from the Pharmaceutical Trade and Supply Chain Survey fielded between 07 July and 30 July 2020.